Aleniglipron
ACCESS
Gasherbrum Bio, Inc · Phase 2 · Completed · Enrollment 230
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Cohort 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 1 OLE | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 2 OLE | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 3 OLE | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 4 OLE | Obesity or overweight | n/r | n/r | n/r | n/r |